Skip to main content
-
Diagnostic Services
- New Tests
- Test Methodologies
-
Specialty Testing
- Hemopathology
- Solid Tumors
- Immuno-Oncology
- NeoTYPE® Cancer Profiles
- NeoLAB™ Liquid Biopsy
- NCI-MATCH
- Pediatric Oncology
- Hereditary Cancer
- Test Spotlight
- Tech-Only Program
- Get Started with NeoGenomics
-
Pharma Services
- Pharma Services
- Why Choose NeoGenomics
- Lab Services
- IVD Services
- Oncology Data Services
- Request More Information
- Test Menu
- Client Services
- Company
- NEOLINK ® LOG IN
Search Form Mobile Toggle
Mobile Menu Toggle
-
NeoGenomics Acquires Oncology Division from Human Longevity for $37 MillionRead More -
A consultative diagnostic solution for complex hematologic malignanciesCOMPASS®
-
NEOGENOMICS NEWSNeoGenomics to Build State-of-the-Art Oncology Laboratory and Global Headquarters in Fort Myers, FloridaRead More
-
PIK3CA CDxInforming a new biomarker-driven strategyfor HR+/HER2- advanced breast cancerMutation Analysis
-
FGFR CDxA Novel Approach to Target Metastatic Urothelial CancerClick Here
-
NeoGenomics Launches Immuno-Oncology Companion Diagnostic Test for Triple Negative Breast Cancer in Conjunction with FDA Approval for TECENTRIQ®Read More
-
NEOGENOMICS NEWSQIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugsRead More
-
CancerTYPE ID®Learn MoreNow also available through NeoGenomics - for unclear or unknown diagnoses in solid tumorsPerformed and billed separately by our contracted reference laboratory, Biotheranostics, Inc.
Close Menu